Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P
Bibliographic record
Abstract
Abstract Background: DUSP22- and TP63-rearranged ALK- ALCL are distinct genetic subtypes with unique disease phenotypes and reported variability in overall survival. The ECHELON-2 study established BV-CHP as the standard upfront therapy in for treating systemic anaplastic large cell lymphoma (sALCL). However, disease or patient features that predicted outcomes for patients (pts) with sALCL treated with CHOP/CHOEP may not apply for BV-CHP/CHEP-treated pts. We conducted a multicenter, retrospective analysis of pts with ALK-negative sALCL treated with BV-based multiagent chemotherapy (BV-CHP/CHEP) seeking to establish outcomes achieved and determine the impact of DUSP22 and/or TP63 rearrangements in this setting. Methods: We identified all pts with ALK-negative sALCL receiving frontline BV-based multiagent chemotherapy from 2012 to 2024 at each center. Treatment may have occurred in a clinical trial or as standard-of-care. FISH testing for gene rearrangements and IHC testing for sALCL markers was performed at each site per standard procedures. We used descriptive statistics to characterize the population and Kaplan-Meier methods to calculate PFS and overall survival (OS) from date of diagnosis. Comparisons between survival trajectories and analysis of clinical/disease features (baseline age, stage III/IV, elevated LDH, IPI score, presence of cytotoxic marker(s), TP63/DUSP22 rearrangement status, and receipt of transplant) influencing PFS and OS were performed using the log-rank test. Results: We identified 112 pts across 8 centers in the United States and Canada. The median age at diagnosis was 59 years (range, 26-86), 38% were female, 85% ECOG 0/1, and 70 (67%) had stage III or IV disease. 93/112 pts had all baseline IPI variables documented, of which 34 (37%) were IPI 0 or 1, 46 (50%) 2 or 3, and 13 (14%) 4 or 5. DUSP22 rearrangement was present in 25/90 (28%) cases, TP63 rearrangement in 6/82 (7%), and there were 3 cases with concurrent DUSP22/TP63 rearrangement. Relevant tumor markers included CD3+ in 59%, CD4+ in 76%, CD7+ in 23%, and CD8+ in 26%. The frequency of cytotoxic IHC marker positivity was as follows: TIA-1 in 43%, granzyme B in 38%, and perforin in 50%; 76 cases had at least one of these three markers tested and 37 (49%) were positive for ≥1 marker. The initial treatment was predominantly BV-CHP (88%), less frequently BV-CHEP (12%). Ninety-six (86%) pts received 6 cycles, and the reasons for receiving <6 cycles were interim CR response in 7 pts, unknown in 4, progressive disease in 3, and toxicity in 2. The end-of-induction response rate was 89%, including 79% CR, and 34 (33%) pts underwent consolidative transplant (autoHCT, 32; alloHCT, 2). Twenty-one pts whose disease initially responded later experienced relapse. With a median follow-up of 29 months (range, 0.5-150) among survivors, median PFS and OS were 67 months (95% CI: 37.7-NR) and 94 (95% CI: 91.2-NR), respectively. The 2-year PFS and OS rates were 66% (56-77) and 83% (76-92), respectively. The 2-year OS did not significantly differ by DUSP22 rearrangement: 94% present (95% CI: 84-100) vs. 86% absent (95% CI: 76-97). Pts whose ALCL harbored TP63 rearrangement had inferior 1- and 2-year PFS that did not reach the threshold for statistical significance: 50% vs. 82% and 50% vs. 64%, respectively (P = 0.2). One of the 3 pts with dual DUSP22/TP63-rearranged disease remains in remission, one died following relapse and one has just completed treatment. 25 of the pts who attained end-of-treatment CR underwent autoHCT and their 1-year and 2-year PFS rates were 83% (95% CI: 70-100) and 74% (95% CI: 58-95), respectively. Considering predictors of PFS/OS, IPI 2-3 (P = 0.02), 4-5 (P = 0.0007), and stage III/IV (P = 0.02) conferred inferior PFS. Only IPI 2-3 (P = 0.05) and 4-5 (P = 0.006) associated with inferior OS. Conclusions: This cohort, the largest of ALK- sALCL pts treated with frontline BV-based chemotherapy reported since the original publication of ECHELON 2, confirms the high activity of BV-based multiagent chemotherapy regimens. Pts with sALCL harboring TP63 rearrangement fared worse but the outcomes appeared better than previous reports in this subpopulation. Our data suggest that DUSP22 rearrangement status may not significantly affect outcomes in BV-CHP/CHEP-treated pts. High IPI score and advanced stage were associated with inferior PFS.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".